培训课件--胃癌B.pptVIP

* A superior response rate was observed for Xeloda/cisplatin vs. 5-FU/cisplatin p 0.030 , supporting the general trend to superiority seen in other efficacy endpoints. Tumor responses were assessed according to Response Evaluation Criteria in Solid Tumors RECIST specifications. Overall response is the sum of confirmed complete and partial responses. Three complete responses were observed in Xeloda/cisplatin groups vs. 4 complete responses in the 5-FU/cisplatin group. Patients in the Xeloda/cisplatin group had 1.4 times the chance of achieving an overall response compared to patients in t